Zydus Cadila gets 180-day exclusivity for Tofacitinib extendedrelease 22 mg tablets, announces final approval from USFDA

Zydus Cadila has received final approval from the USFDA to market Tofacitinib extendedrelease tablets, 11 mg and 22 mg in the United States (ANDA-214264 and US RLD: XELJANZ XR). Zydus was the first ANDA filer on Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength.

Tofacitinib extended-release tablets had annual sales of approximately $2,082 million in the United States for the year ending June 2021 according to IQVIA data. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 321 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Ltd. was last trading in BSE at Rs. 535.2 as compared to the previous close of Rs. 542.7. The total number of shares traded during the day was 287374 in over 7899 trades.

The stock hit an intraday high of Rs. 547.85 and intraday low of 522. The net turnover during the day was Rs. 154172166.

Source : Equity Bulls

Keywords